Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, NovoCure Ltd (NASDAQ: NVCR) closed at $10.92 down -3.11% from its previous closing price of $11.27. In other words, the price has decreased by -$3.11 from its previous closing price. On the day, 2.23 million shares were traded. NVCR stock price reached its highest trading level at $11.1165 during the session, while it also had its lowest trading level at $10.7.
Ratios:
For a deeper understanding of NovoCure Ltd’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 0.70.
On July 08, 2025, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $30.
Evercore ISI Upgraded its In-line to Outperform on December 02, 2024, whereas the target price for the stock was revised from $18 to $30.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 05 ’25 when Cordova Ashley bought 81,550 shares for $12.22 per share. The transaction valued at 996,859 led to the insider holds 437,569 shares of the business.
Brackmann Christoph bought 20,000 shares of NVCR for $231,800 on Jul 29 ’25. The Chief Financial Officer now owns 141,150 shares after completing the transaction at $11.59 per share. On Jun 03 ’25, another insider, Stafford Kristin, who serves as the Director of the company, sold 999 shares for $17.28 each. As a result, the insider received 17,259 and left with 3,054 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCR now has a Market Capitalization of 1222843264 and an Enterprise Value of 987283264. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.90 while its Price-to-Book (P/B) ratio in mrq is 3.58. Its current Enterprise Value per Revenue stands at 1.537 whereas that against EBITDA is -6.198.
Stock Price History:
The Beta on a monthly basis for NVCR is 0.85, which has changed by -0.39967012 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, NVCR has reached a high of $34.13, while it has fallen to a 52-week low of $10.87. The 50-Day Moving Average of the stock is -16.46%, while the 200-Day Moving Average is calculated to be -33.54%.
Shares Statistics:
For the past three months, NVCR has traded an average of 1.53M shares per day and 1573040 over the past ten days. A total of 111.98M shares are outstanding, with a floating share count of 99.52M. Insiders hold about 11.14% of the company’s shares, while institutions hold 84.07% stake in the company. Shares short for NVCR as of 1760486400 were 5242339 with a Short Ratio of 3.43, compared to 1757894400 on 5886314. Therefore, it implies a Short% of Shares Outstanding of 5242339 and a Short% of Float of 7.39.
Earnings Estimates
The dynamic stock of NovoCure Ltd (NVCR) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.32 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.31 and -$1.5 for the fiscal current year, implying an average EPS of -$1.38. EPS for the following year is -$1.51, with 8.0 analysts recommending between -$1.19 and -$1.91.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $168.34M this quarter.It ranges from a high estimate of $178.4M to a low estimate of $158.28M. As of. The current estimate, NovoCure Ltd’s year-ago sales were $161.27MFor the next quarter, 8 analysts are estimating revenue of $168.39M. There is a high estimate of $175.2M for the next quarter, whereas the lowest estimate is $159.37M.
A total of 7 analysts have provided revenue estimates for NVCR’s current fiscal year. The highest revenue estimate was $663M, while the lowest revenue estimate was $639.29M, resulting in an average revenue estimate of $650.8M. In the same quarter a year ago, actual revenue was $605.22MBased on 8 analysts’ estimates, the company’s revenue will be $688.78M in the next fiscal year. The high estimate is $738.9M and the low estimate is $658.79M.
